Concordia International Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. It operates through three segments: Concordia International, Concordia North America, and Orphan Drugs. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies. This segments products include Tetroxin drug for severe hypothyroid states; Macrobid/Macrodantin to treat bladder infections, such as cystitis and urinary tract infections; Fucithalmic, a topical gel treatment for patients suffering with a bacterial infection of the surface lining of the front of the eye; and Eltroxin, levothyroxine sodium that treats patients with an underactive thyroid gland. The Concordia North America segment provides Donnatalm, which is used as adjunctive therapy for irritable bowel syndrome; Plaquenil and Plaquenil AG to treat rheumatoid arthritis and manage the complications of lupus, as well as suppress acute attacks from certain strains of malaria; and Zonegran, an anti-seizure drug indicated for adjunctive therapy in the treatment of partial seizures in adults with epilepsy. The Orphan Drugs segment develops Photofrin, a light-based cancer treatment that combines a photosensitizing drug called porfimer sodium with a specific type of light to attack cancer cells. The company sells through direct sales and local partnerships. The company was formerly known as Concordia Healthcare Corp. and changed its name to Concordia International Corp. in 2016. Concordia International Corp. is headquartered in Oakville, Canada.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: TSE:CXR
- CUSIP: N/A
- Web: concordiarx.com
- Market Cap: C$78.76 million
- Outstanding Shares: 51,089,000
- 50 Day Moving Avg: C$1.85
- 200 Day Moving Avg: C$2.15
- 52 Week Range: C$1.41 - C$12.24
Sales & Book Value:
- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
- Annual Revenue: C$677.25 million
- Price / Sales: 0.12
- Book Value: C($27.60) per share
- Price / Book: -0.06
- EBIDTA: C$326.58 million
- Net Margins: -49.09%
- Return on Assets: -8.60%
- Average Volume: 219,759 shs.
- Short Ratio: 0.8
Frequently Asked Questions for Concordia International Corp (TSE:CXR)
What is Concordia International Corp's stock symbol?
Concordia International Corp trades on the Tornton Stock Exchange (TSX) under the ticker symbol "CXR."
How were Concordia International Corp's earnings last quarter?
Concordia International Corp (TSE:CXR) posted its earnings results on Thursday, August, 13th. The company reported $1.04 earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of $1.06 by $0.02. The business earned $95.34 million during the quarter, compared to analysts' expectations of $87.41 million. View Concordia International Corp's Earnings History.
When will Concordia International Corp make its next earnings announcement?
Where is Concordia International Corp's stock going? Where will Concordia International Corp's stock price be in 2017?
4 brokerages have issued twelve-month price objectives for Concordia International Corp's stock. Their forecasts range from C$13.50 to C$14.00. On average, they expect Concordia International Corp's stock price to reach C$13.75 in the next year. View Analyst Ratings for Concordia International Corp.
Who are some of Concordia International Corp's key competitors?
Some companies that are related to Concordia International Corp include VBI Vaccines (VBIV), Mirati Therapeutics (MRTX), ContraFect Corporation (CFRX), XOMA Corporation (XOMA), Aevi Genomic Medicine (GNMX), Trillium Therapeutics (TRIL), Ohr Pharmaceuticals (OHRP), Humanigen (KBIO), Can Fite Biopharma Ltd (CANF), Soligenix (SNGX), Soligenix (SNGX), Mateon Therapeutics (MATN), Windtree Therapeutics (WINT), Affymax (AFFY), CSL Limited (CSL), Cubist Pharmaceuticals (CBST), Dendreon (DNDN) and DNIB Unwind (BIND).
Who are Concordia International Corp's key executives?
Concordia International Corp's management team includes the folowing people:
- Jordan M. Kupinsky J.D., Chairman of the Board
- Wayne Kreppner, President, Chief Operating Officer
- Allan Oberman, Chief Executive Officer, Director
- David J. Price, Chief Financial Officer
- Graeme Duncan, President - Company's International Segment
- Arijit Mookerjee, Managing Director, Chief Financial Officer - Operations
- Adeel Ahmad, Chief Financial Officer of AMCo
- Francesco Tallarico, Chief Legal Officer and Secretary
- Patrick Vink M.D., Director
- Douglas N. Deeth, Independent Director
How do I buy Concordia International Corp stock?
Shares of Concordia International Corp and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.
What is Concordia International Corp's stock price today?
MarketBeat Community Rating for Concordia International Corp (TSE CXR)MarketBeat's community ratings are surveys of what our community members think about Concordia International Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Concordia International Corp stock can currently be purchased for approximately C$1.54.
Consensus Ratings for Concordia International Corp (TSE:CXR) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||4 Sell Ratings|
|Consensus Rating:||Sell (Score: 1.00)|
|Consensus Price Target: ||C$13.75|
Analysts' Ratings History for Concordia International Corp (TSE:CXR)
(Data available from 8/19/2015 forward)
|2/9/2017||TD Securities||Downgrade||Hold -> Reduce|
|12/8/2016||Royal Bank Of Canada||Downgrade||Sector Perform -> Underperform|
|11/7/2016||Bloom Burton||Downgrade||Hold -> Sell|
|8/15/2016||Goldman Sachs Group, Inc. (The)||Lower Price Target||C$34.00 -> C$17.00|
|8/15/2016||CIBC||Downgrade||Sector Perform -> Underperform|
|3/21/2016||Dundee Securities||Lower Price Target||C$62.00 -> C$60.00|
|9/9/2015||Canaccord Genuity||Boost Price Target||C$95.00 -> C$100.00|
Earnings History for Concordia International Corp (TSE:CXR)Earnings History by Quarter for Concordia International Corp (TSE CXR)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/6/2017|| || || || || || || || |
|8/13/2015||Q2||$1.06||$1.04||$87.41 million||$95.34 million||View||Listen|
|8/13/2014||$0.19||($0.03)||$24.42 million||$28.49 million||View||N/A|
Earnings Estimates for Concordia International Corp (TSE:CXR)
Current Year EPS Consensus Estimate: $0.54 EPS
Dividend History by Quarter for Concordia International Corp (TSE CXR)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Concordia International Corp (TSE:CXR)Insider Trades by Quarter for Concordia International Corp (TSE:CXR)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|5/25/2017||Erin Colleen O'neil||Director||Sell||191||C$1.74||C$332.34|
|5/16/2017||Graeme Neville Duncan||Director||Sell||7,065||C$1.91||C$13,494.15|
|2/1/2016||Mark Laurence Thompson||Director||Buy||60||C$28.77||C$1,726.20|
|11/17/2015||Wayne Walter Kreppner||Insider||Buy||3,000||C$43.67||C$131,010.00|
|11/16/2015||Mark Laurence Thompson||Director||Buy||23,150||C$43.36||C$1,003,702.98|
|7/17/2015||Wayne Walter Kreppner||Insider||Sell||4,800||C$103.00||C$494,400.00|
|6/26/2015||Robert Steven Altman||Insider||Sell||62,500||C$93.93||C$5,870,893.75|
|5/27/2015||Saldanha Adrian De||Insider||Buy||1,000||C$80.61||C$80,610.00|
|10/31/2014||James Christopher Reebals||Director||Sell||7,500||C$37.25||C$279,360.75|
|10/30/2014||James Christopher Reebals||Director||Sell||7,500||C$37.06||C$277,926.75|
|10/29/2014||James Christopher Reebals||Director||Sell||5,000||C$37.07||C$185,336.50|
Headline Trends for Concordia International Corp (TSE:CXR)
Latest Headlines for Concordia International Corp (TSE:CXR)
|Concordia International Corp. :CXR-CA: Earnings Analysis: Q2, 2017 By the Numbers : August 18, 2017|
finance.yahoo.com - August 18 at 5:40 PM
|RedHill Biopharma Announces US Commercialization Agreement for FDA-Approved GI Product Esomeprazole ... - Nasdaq|
www.nasdaq.com - August 17 at 4:32 PM
|SHAREHOLDER ALERT: Morganti Legal, PC Advises Shareholders of Concordia International Corp. of a Motion ... - Business Wire (press release)|
www.businesswire.com - August 15 at 6:24 PM
|Edited Transcript of CXR.TO earnings conference call or presentation 11-Aug-17 12:30pm GMT|
finance.yahoo.com - August 11 at 11:12 PM
|Concordia International Corp (TSE:CXR) Set to Announce Earnings on Friday|
www.americanbankingnews.com - August 4 at 7:12 AM
|Concordia International Corp. :CXR-CA: Earnings Analysis: Q1, 2017 By the Numbers : August 3, 2017|
finance.yahoo.com - August 3 at 7:15 PM
|Short seller Cohodes hits Canada again with latest target -Exchange Income|
www.nasdaq.com - July 5 at 6:28 PM
|Concordia Shares Lead TSX Gainers on Corporate Update|
www.baystreet.ca - June 22 at 10:32 AM
|Canadian Healthcare Stocks Under Review Concordia International, ProMetic Life Sciences, Theratechnologies, and Cardiome Pharma|
finance.yahoo.com - June 9 at 8:27 AM
|Concordia International Corp. Announces Results of First CMA Stop/Go Decision - PR Newswire (press release)|
www.prnewswire.com - May 31 at 9:39 PM
|Concordia International Corp (CXR) Given Consensus Rating of "Sell" by Analysts|
www.americanbankingnews.com - May 23 at 7:48 AM
|Concordia International Corp (CXR) Director Graeme Neville Duncan Sells 7,065 Shares|
www.americanbankingnews.com - May 17 at 8:34 PM
|Concordia International Corp (CXR) PT Lowered to C$0.35|
www.americanbankingnews.com - May 12 at 1:02 PM
|Edited Transcript of CXR.TO earnings conference call or presentation 10-May-17 12:30pm GMT|
finance.yahoo.com - May 10 at 9:49 PM
|Concordia International Corp. Announces Two New Appointments to ... - PR Newswire (press release)|
www.prnewswire.com - May 4 at 8:02 AM
|Concordia International Corp. Announces Release Date for First Quarter 2017 Results|
finance.yahoo.com - May 2 at 8:03 PM
|Concordia International Corp (CXR) Given Consensus Recommendation of "Sell" by Analysts|
www.americanbankingnews.com - April 28 at 10:37 AM
|Concordia International Appoints David Price as Chief Financial Officer|
finance.yahoo.com - April 27 at 1:48 AM
|Canadian Stocks Are Extending Recent Losses - Canadian Commentary|
www.nasdaq.com - April 13 at 11:46 AM
|Concordia International Corp (CXR) Given Average Rating of "Sell" by Analysts|
www.americanbankingnews.com - April 3 at 1:42 PM
|Canadian Stocks Are Paring Early Gains - Canadian Commentary|
www.nasdaq.com - March 17 at 9:58 PM
|Stocks Rally On Oil Rebound, Sober Fed -- Canadian Commentary|
www.nasdaq.com - March 15 at 5:04 PM
|Concordia International Announces Fourth Quarter and Fiscal 2016 Results|
finance.yahoo.com - March 15 at 9:47 AM
|Q4 2016 Concordia International Corp Earnings Release - Before Market Open|
biz.yahoo.com - March 15 at 9:47 AM
|RedHill Biopharma's Co-Promotion Partner Concordia Announces ... - Nasdaq|
www.nasdaq.com - March 7 at 4:34 PM
|Concordia International Corp. Grant of Treble Damages Further Vindicates Marketing Rights of its Donnatal® Brand - Yahoo Finance|
finance.yahoo.com - March 7 at 4:34 PM
|Profile: Concordia International Corp (CXR.TO)|
www.reuters.com - February 7 at 10:47 PM
|Canadian Stocks Are Extending Their Losses In Early Trade - Canadian Commentary - Nasdaq|
www.nasdaq.com - January 31 at 5:15 PM
|Concordia International Corp. Announces Leadership Transition at International Segment|
finance.yahoo.com - December 28 at 11:59 AM
|TSX Slightly Higher, Blackberry Makes Bet On Self-driving Cars|
www.rttnews.com - December 20 at 5:23 PM
Concordia International Corp (CXR) Chart for Saturday, August, 19, 2017